Income Statement Merchavia Holdings and Investments Ltd
Equities
MRHL
IL0002570146
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 184.10 ILa | +0.05% |
|
+0.27% | -14.57% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Gain (Loss) on Sale of Investment, Total (Rev) | 10.06M | 4.02M | 1.72M | 71K | - | |||||
Interest And Invest. Income (Rev) | - | 34K | 125K | 48K | 44K | |||||
Other Revenues, Total | 550K | 110K | - | - | - | |||||
Total Revenues | 10.61M | 4.16M | 1.85M | 119K | 44K | |||||
Gross Profit | 10.61M | 4.16M | 1.85M | 119K | 44K | |||||
Selling General & Admin Expenses, Total | 3.4M | 2.72M | 2.39M | 2.83M | 1.92M | |||||
Other Operating Expenses | 59K | -17K | -317K | -324K | -329K | |||||
Other Operating Expenses, Total | 3.46M | 2.7M | 2.07M | 2.51M | 1.59M | |||||
Operating Income | 7.15M | 1.46M | -221K | -2.39M | -1.54M | |||||
Interest Expense, Total | - | - | - | - | -12K | |||||
Interest And Investment Income | - | - | - | - | - | |||||
Net Interest Expenses | - | - | - | - | -12K | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | -26K | 13K | 18K | 1K | 25K | |||||
Other Non Operating Income (Expenses) | - | - | -2K | 1.5M | 15K | |||||
EBT, Excl. Unusual Items | 7.12M | 1.47M | -205K | -888K | -1.51M | |||||
Gain (Loss) On Sale Of Investments | -1.27M | -5.08M | -16.03M | -6.08M | -8.65M | |||||
EBT, Incl. Unusual Items | 5.85M | -3.61M | -16.23M | -6.97M | -10.16M | |||||
Earnings From Continuing Operations | 5.85M | -3.61M | -16.23M | -6.97M | -10.16M | |||||
Net Income to Company | 5.85M | -3.61M | -16.23M | -6.97M | -10.16M | |||||
Net Income - (IS) | 5.85M | -3.61M | -16.23M | -6.97M | -10.16M | |||||
Net Income to Common Incl Extra Items | 5.85M | -3.61M | -16.23M | -6.97M | -10.16M | |||||
Net Income to Common Excl. Extra Items | 5.85M | -3.61M | -16.23M | -6.97M | -10.16M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.36 | -0.21 | -0.96 | -0.41 | -0.5 | |||||
Basic EPS - Continuing Operations | 0.36 | -0.21 | -0.96 | -0.41 | -0.5 | |||||
Basic Weighted Average Shares Outstanding | 16.27M | 17.32M | 16.97M | 17.04M | 20.12M | |||||
Net EPS - Diluted | 0.35 | -0.21 | -0.96 | -0.41 | -0.5 | |||||
Diluted EPS - Continuing Operations | 0.35 | -0.21 | -0.96 | -0.41 | -0.5 | |||||
Diluted Weighted Average Shares Outstanding | 16.27M | 17.32M | 16.97M | 17.04M | 20.12M | |||||
Normalized Basic EPS | 0.27 | 0.05 | -0.01 | -0.03 | -0.05 | |||||
Normalized Diluted EPS | 0.27 | 0.05 | -0.01 | -0.03 | -0.05 | |||||
Supplemental Items | ||||||||||
EBITDA | 7.16M | 1.47M | -209K | -2.38M | -1.54M | |||||
EBITA | 7.15M | 1.46M | -221K | -2.39M | -1.54M | |||||
EBIT | 7.15M | 1.46M | -221K | -2.39M | -1.54M | |||||
Total Revenues (As Reported) | 10.61M | 4.26M | 2.18M | 1.94M | 415K | |||||
Normalized Net Income | 4.45M | 921K | -128K | -555K | -946K | |||||
Interest on Long-Term Debt | - | - | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 3.4M | 2.72M | 2.39M | 2.83M | 1.92M | |||||
Stock-Based Comp., G&A Exp. (Total) | 1.21M | 660K | 216K | 812K | 1K | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 1.21M | 660K | 216K | 812K | 1K |
Select your edition
All financial news and data tailored to specific country editions
















